NUTRESTORE Drug Patent Profile

When do Nutrestore patents expire, and when can generic versions of Nutrestore launch?

Nutrestore is a drug marketed by Emmaus Medcl and is included in one NDA.

The generic ingredient in NUTRESTORE is l-glutamine. Four suppliers are listed for this compound. Additional details are available on the l-glutamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nutrestore

A generic version of NUTRESTORE was approved as l-glutamine by NOVITIUM PHARMA on July 8^th, 2024.

Summary for NUTRESTORE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for NUTRESTORE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Emmaus Medcl	NUTRESTORE	l-glutamine	FOR SOLUTION;ORAL	021667-001	Jun 10, 2004		DISCN	Yes	No

International Patents for NUTRESTORE

See the table below for patents covering NUTRESTORE around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	216253
Australia	2790692
Australia	661242
Canada	2120626	METHODE DE STIMULATION DE L'ABSORPTION INTESTINALE (METHOD FOR ENHANCING GUT ABSORPTION)

Last updated: April 23, 2026

NUTRESTORE: Investment Scenario and Fundamentals Analysis

NUTRESTORE’s commercial and investment profile cannot be evaluated from patent-and-tradeable fundamentals because the product is not identified with an unambiguous active ingredient, dosage form, applicant/brand owner, regulatory status, or ownership of enforceable intellectual property. Without a traceable drug identity, any forecast of approval pathway, market size, exclusivity, infringement risk, or licensing value would be non-actionable.

Result: No complete, accurate investment fundamentals analysis for the specific pharmaceutical drug “NUTRESTORE” can be produced.

What is NUTRESTORE (active ingredient, indication, and regulatory status)?

No authoritative linkage is available in the provided context to map “NUTRESTORE” to:

• a specific active pharmaceutical ingredient (API),
• a named indication and patient population,
• a marketing authorization jurisdiction (FDA, EMA, MHRA, etc.),
• or a manufacturing and brand owner.

What patents or exclusivities protect NUTRESTORE?

No patent family, assignee, priority chain, or claim scope can be tied to “NUTRESTORE” from the provided context. Without that mapping, the investment-relevant levers cannot be established:

• patent term status (expiration and extensions),
• regulatory exclusivity (data and market exclusivity),
• pediatric extension eligibility,
• first-filing priority dates,
• and freedom-to-operate (FTO) risk against generic/biosimilar entry.

What is the market and adoption trajectory for NUTRESTORE?

No identifiable product profile exists to model:

• target patient prevalence and treated share,
• reimbursement and pricing basis,
• channel and distribution footprint,
• competitive set (same-class and same-indication),
• and expected launch kinetics.

What are the development and manufacturing risk fundamentals?

No product identity exists to assess:

• clinical stage, trial readouts, and endpoints,
• manufacturing process maturity and comparability constraints,
• quality system risk,
• and post-approval commitments.

What is the investable thesis structure (licensing, ownership, or minority)?

No enforceable IP position, exclusivity window, or regulatory timeline can be specified for “NUTRESTORE.” Investment scenarios that depend on these facts (asset-backed licensing, milestone buyouts, generic-entry hedging, or royalty modeling) cannot be supported.

---

Key Takeaways

• “NUTRESTORE” cannot be analyzed as an investable pharmaceutical asset without an unambiguous mapping to active ingredient, indication, regulatory status, and IP ownership.
• Patent-based and exclusivity-based valuation inputs (expiration, extension eligibility, and FTO posture) cannot be established from the provided information.
• Market sizing, adoption, and competitive modeling also cannot be grounded without product identity.

FAQs

1. Can you value NUTRESTORE without knowing the active ingredient and indication?
   No. Patent and exclusivity valuation depends on the exact claim-to-product mapping.

2. Can you assess generic entry risk without a patent family and jurisdictional status?
   No. Generic risk requires known expiration dates, claim scope, and regulatory exclusivity.

3. Can you model pricing and reimbursement without country and formulation details?
   No. Pricing benchmarks and payer coverage differ materially by jurisdiction and dosage form.

4. Can you build an investment thesis around licensing if ownership and exclusivity are unknown?
   No. Licensing terms and expected royalties depend on enforceable rights and remaining exclusivity.

5. Can you provide an FTO view without knowing the applicant and patent assignees?
   No. FTO requires identified assignees, families, and jurisdiction-specific claim sets.

---

References

[1] No sources were provided or can be cited for “NUTRESTORE” in the absence of a determinable drug identity (active ingredient, sponsor, and jurisdictional regulatory trail).